Related Experiment Video
Updated: Jun 23, 2026
Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay
Published on: September 10, 2018
Anti-PLA2R antibody reduction as a predictor of treatment response in primary membranous nephropathy: a retrospective
Khuram Bashir1, Muhammad Rashid Asghar1, Nayyar Saleem1
1Multan Institute of Kidney Diseases, Multan, Punjab, Pakistan.
Introduction:
Primary membranous nephropathy (PMN) is a leading cause of nephrotic syndrome in adults. Although proteinuria has been the conventional guiding parameter in disease monitoring, its limitations as a non-specific and delayed marker have led to the appeal of anti-phospholipase A2 receptor antibodies (PLA2R) as specific and sensitive indicators of disease activity and response to treatment.
Methods:
This retrospective cohort study included 60 patients with biopsy-proven PMN and positive baseline anti-PLA2R antibodies who underwent treatment at the Multan Institute of Kidney Diseases. Anti-PLA2R levels were measured at baseline and at the 6-month follow-up using enzyme-linked immunosorbent assay (ELISA). Clinical remission was assessed using the standard proteinuria and renal function criteria. Statistical analyses included receiver operating characteristic (ROC) curves, logistic regression, and correlation assessments.
Results:
Baseline anti-PLA2R levels were significantly lower in patients who achieved remission (p = 0.047), and 6-month levels showed a strong correlation with treatment response (p < 0.001). ROC analysis demonstrated good predictive accuracy with area under curve (AUC) of 0.707 (baseline) and 0.815 (6-month), identifying optimal remission cutoffs at 125.5 RU/mL and 37.75 RU/mL, respectively. Logistic regression analysis confirmed the baseline albumin level, 6-month anti-PLA2R, and proteinuria reduction as independent predictors of remission.
Conclusion:
Anti-PLA2R antibody levels at baseline and 6 months serve as robust predictors of treatment response in PMN and outperform proteinuria in early remission assessment. These findings support the integration of anti-PLA2R monitoring into standard clinical practice for personalized management and therapy adjustment in PMN.
Insights
Anti-phospholipase A2 receptor (PLA2R) antibody levels predict treatment response in primary membranous nephropathy (PMN) better than proteinuria. Monitoring PLA2R levels aids in early remission assessment and personalized management of PMN.
Area of Science:
- Nephrology
- Immunology
- Clinical Medicine
Background:
- Primary membranous nephropathy (PMN) is a major cause of nephrotic syndrome in adults.
- Proteinuria is a conventional but limited marker for monitoring PMN.
- Anti-phospholipase A2 receptor (PLA2R) antibodies are emerging as specific indicators of PMN activity.
Purpose of the Study:
- To evaluate anti-PLA2R antibody levels as predictors of treatment response in PMN.
- To compare the efficacy of PLA2R antibodies versus proteinuria in assessing early remission.
- To support the integration of PLA2R monitoring into clinical practice for PMN management.
Main Methods:
- Retrospective cohort study of 60 biopsy-proven PMN patients with positive baseline anti-PLA2R antibodies.
- Measurement of anti-PLA2R levels at baseline and 6 months via ELISA.
- Assessment of clinical remission using proteinuria and renal function criteria; statistical analysis included ROC curves and logistic regression.
Main Results:
- Lower baseline anti-PLA2R levels were observed in patients achieving remission (p=0.047).
- Six-month anti-PLA2R levels strongly correlated with treatment response (p<0.001).
- ROC analysis showed good predictive accuracy (AUC 0.707 at baseline, 0.815 at 6 months); baseline albumin, 6-month anti-PLA2R, and proteinuria reduction independently predicted remission.
Conclusions:
- Anti-PLA2R antibody levels at baseline and 6 months are robust predictors of treatment response in PMN.
- PLA2R antibody monitoring surpasses proteinuria for early remission assessment in PMN.
- Findings advocate for incorporating anti-PLA2R monitoring into standard PMN clinical practice for personalized therapy.
More Related Videos
06:07Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
